Bundle Offer from La Merie Publishing

Market Publishers is extremely happy to announce a great discount opportunity on behalf of La Merie Publishing, our Germany-based research partner.

From now all Market Publishers’ customers can become owners of a bundle of market research studies prepared by our partner at a discounted price.

The studies cover:

  • Antibody-Drug Conjugates
  • Biosimilar and Biosuperior Therapeutic Antibodies
  • T-Cell Redirecting Bispecific Antibodies
  • Bispecific Antibodies for Cancer, Inflammatory and Other Diseases

Please, find prices for the bundle below:

License Price in EUR (€) Price in USD ($)
Single User 3,100 3,500
Site License 6,200 7,000
Global License    9,300 10,500

By getting simultaneously all four reports mentioned above you will be given a 50% discount on all license types.

Are you interested in this offer? Do not hesitate any more, send us an email.

Found 9 publications
mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals US$ 2,520.00

... with mRNA technology companies. At least 16 mRNA vaccines and therapeutics are in clinical stages and a considerable number is in IND or pre-IND stage. This report mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals as of June 2017 brings you up-to-date regarding key mRNA players, key mRNA technologies and applications, mRNA vaccines & therapeutics ...

Jun, 2017 260 pages
Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017 US$ 450.00

Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017 This Competitive Intelligence Report about RSV Antibodies, Vaccines & Antivirals provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules, protein and peptide therapeutics against infection caused by respiratory syncytial virus (RSV ...

Mar, 2017 53 pages
Competitor Analysis: Kallikrein Inhibitors 2017 US$ 170.00

Competitor Analysis: Kallikrein Inhibitors & Bradykinin Receptor Antagonists The present Competitive Intelligence report aboutKallikrein Inhibitors & Bradykinin Receptor Antagonists provides a competitor evaluation in the field of marketed and ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

Apr, 2017 17 pages
Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars US$ 230.00

Competitor Analysis: Complement C5 Inhibitors 2017 Biosuperiors & Biosimilars This Competitive Intelligence report about Complement C5 Inhibitors 2017 Biosuperiors & Biosimilars provides a competitor evaluation in the field of mainly recombinant antibodies ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

Mar, 2017 21 pages
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update US$ 1,393.00

... about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar ... , pavilizumab, tocilizumab, and ustekinumab. Download sample pages of Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update Competitor projects are listed in a tabular format providing information ...

May, 2016 462 pages
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases US$ 560.00

Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory Other Diseases This Competitive Intelligence report about Bispecific Antibodies for Cancer, Inflammatory Other Diseases evaluates the competitive ... as: T-Cell or NK cell redirecting bispecific cancer antibodies Bispecific immuno-oncology antibodies Bispecific tumor antigens targeted cancer antibodies Bispecific antibodies for inflammatory autoimmune diseases Bispecific antibodies for cardiometabolic, infectious, neurologic ...

Jun, 2016 180 pages
T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals US$ 2,197.00

... T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months. This report T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals “ as of May 2016 brings you up-to-date information ...

May, 2016 230 pages
Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins US$ 160.00

Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins This report prepared by La Merie Publishing provides a compilation of the sales data of originator recombinant therapeutic proteins and ... of blockbuster biologics with 2016 sales higher than US$ 1 bln. Another ranking list was prepared for TOP 30 companies according to biologics sales in 2016 and the percentage of antibody sales of total biologics sales.

Mar, 2017 45 pages
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis US$ 2,519.00

... same number of ADC programs are in preclinical R&D. Download Samples Pages: Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis For the first ... entitled „Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis“ is based on the analysis of more than 90 companies, more than 100 ADC drug profiles ...

Nov, 2015 470 pages
Skip to top